lunes, 25 de octubre de 2010

Propiedad Intelectual según Stiglitz...y la RSC según Novartis

The establishment of the World Trade Organization … imposed US style intellectual property rights around the world. These rights were intended to reduce access to generic medicines and they succeeded.

Developing countries paid a high price for this agreement. But what have they received in return? Drug companies spend more on advertising and marketing than on research, more on research on lifestyle drugs than on life saving drugs, and almost nothing on diseases that affect developing countries only. This is not surprising. Poor people cannot afford drugs, and drug companies make investments that yield the highest returns. The chief executive of Novartis, a drug company with a history of social responsibility, said “We have no model which would [meet] the need for new drugs in a sustainable way … You can’t expect for-profit organizations to do this on a large scale.”

Joseph Stiglitz (former World Bank Chief Economist and Nobel Prize winner for economics), Scrooge and intellectual property rights, British Medical Journal, December 23, 2006, Volume 333, pp. 1279-1280

Ver tambien

Novartis: Daniel Vasella y la "irresponsabilidad" social "In"...



No hay comentarios: